Furthermore, it has been proposed that the clinical application of PARP inhibitors in prostate cancer could be broadened by combining them with androgen receptor inhibitors, which have been found to suppress the expression of numerous HR genes [27]. The gene discussed is PARP1; the disease is prostate carcinoma.